Alvaro Lassaletta

Alvaro Lassaletta

Auto-generated profile, based on publicly available information

Alvaro Lassaletta

Hospital Infantil Universitario Niño Jesús

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Journal of Clinical Oncology
Verified
Journal Article
Open access
CDCarol Durno
Carol Durno
AEAyse Bahar Ercan
Ayse Bahar Ercan
VBVanessa Bianchi
Vanessa Bianchi
MEMelissa Edwards
Melissa Edwards
MAMelyssa Aronson
Melyssa Aronson
UTUri Tabori
Uri Tabori
PURPOSE: Constitutional mismatch repair deficiency syndrome (CMMRD) is a lethal cancer predisposition syndrome characterized by early-onset synchronous and metachronous multiorgan tumors. We designed a surveillance protocol for early tumor detection in these individuals. PATIENTS AND METHODS: Data were collected from patients with confirmed CMMRD who were registered in the International Replication Repair Deficiency Consortium. Tumor spectrum, efficacy of the surveillance protocol, and malignant transformation of low-grade lesions were examined for the entire cohort. Survival outcomes were analyzed for patients followed prospectively from the time of surveillance implementation. RESULTS: A total of 193 malignant tumors in 110 patients were identified. Median age of first cancer diagnosis was 9.2 years (range: 1.7-39.5 years). For patients undergoing surveillance, all GI and other solid tumors, and 75% of brain cancers were detected asymptomatically. By contrast, only 16% of hematologic malignancies were detected asymptomatically ( P < .001). Eighty-nine patients were followed prospectively and used for survival analysis. Five-year overall survival (OS) was 90% (95% CI, 78.6 to 100) and 50% (95% CI, 39.2 to 63.7) when cancer was detected asymptomatically and symptomatically, respectively ( P = .001). Patient outcome measured by adherence to the surveillance protocol revealed 4-year OS of 79% (95% CI, 54.8 to 90.9) for patients undergoing full surveillance, 55% (95% CI, 28.5 to 74.5) for partial surveillance, and 15% (95% CI, 5.2 to 28.8) for those not under surveillance ( P < .0001). Of the 64 low-grade tumors detected, the cumulative likelihood of transformation from low-to high-grade was 81% for GI cancers within 8 years and 100% for gliomas in 6 years. CONCLUSION: Surveillance and early cancer detection are associated with improved OS for individuals with CMMRD.

25 January 2018 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
ALAlvaro Lassaletta
Alvaro Lassaletta
DSDouglas Strother
Douglas Strother
NLNormand Laperriere
Normand Laperriere
JHJuliette Hukin
Juliette Hukin
MVMagimairajan Issai Vanan
Magimairajan Issai Vanan
EBEric Bouffet
Eric Bouffet

12 December 2019 in The Cerebellum
Verified
Journal Article
Closed access
PDF file
SCSilvia Cámara
Silvia Cámara
MFMª Concepción Fournier
Mª Concepción Fournier
PCPatricia Cordero
Patricia Cordero
JMJavier Melero
Javier Melero
FRFernando Robles
Fernando Robles
MBMarcelo Budke
Marcelo Budke

8 May 2023 in World Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
ÁLÁlvaro Lassaletta
Álvaro Lassaletta
JMJavier S. Morales
Javier S. Morales
PVPedro L. Valenzuela
Pedro L. Valenzuela
BEBorja Esteso
Borja Esteso
LKLisa S. Kahalley
Lisa S. Kahalley
FCFelipe Calvo
Felipe Calvo
Background: Advances in cancer treatments, particularly the development of radiation therapy, have led to improvements in survival outcomes in children with brain tumors. However, radiation therapy is associated with significant long-term neurocognitive morbidity. The present systematic review and meta-analysis aimed to compare the neurocognitive outcomes of children and adolescents with brain tumors treated with photon radiation (XRT) or proton therapy (PBRT).Methods: A systematic search was conducted (PubMed, Embase, Cochrane, and Web of Science from inception until 02/01/2022) for studies comparing the neurocognitive outcomes of children and adolescents with brain tumors treated with XRTvs. PBRT. The pooled mean differences (expressed as Z scores) were calculated using a random effects method for those endpoints analyzed by a minimum of three studies.Results: Totally 10 studies (n = 630 patients, average age range: 1–20 years) met the inclusion criteria. Patients who had received PBRT achieved significantly higher scores (difference in Z scores ranging from 0.29–0.75, allP < 0.05 and significant in sensitivity analyses) after treatment than those who had received XRT for most analyzed neurocognitive outcomes (i.e., intelligence quotient, verbal comprehension and perceptual reasoning indices, visual motor integration, and verbal memory). No robust significant differences (P > 0.05 in main analyses or sensitivity analyses) were found for nonverbal memory, verbal working memory and working memory index, processing speed index, or focused attention.Conclusions: Pediatric brain tumor patients who receive PBRT achieve significantly higher scores on most neurocognitive outcomes than those who receive XRT. Larger studies with long-term follow-ups are needed to confirm these results.

16 July 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
AFAnna Faura
Anna Faura
ÁLÁlvaro Lassaletta
Álvaro Lassaletta
ESElena Sebastián
Elena Sebastián
LMLuis Madero
Luis Madero
JHJorge Huerta
Jorge Huerta
JDJosé Luis Dapena
José Luis Dapena

20 September 2016 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
ALAlvaro Lassaletta
Alvaro Lassaletta
MZMichal Zapotocky
Michal Zapotocky
EBEric Bouffet
Eric Bouffet
CHCynthia Hawkins
Cynthia Hawkins
UTUri Tabori
Uri Tabori